Browse > Article

A Case of Elevated Prothrombin Time-International Normalized Ratio (PT-INR) Associated with Concurrent Use of Erlotinib and Warfarin  

Kim, Seung-Kyoung (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
Park, Kyung-Seon (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
Choi, Seung-Hwa (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
Byun, Jae-Ho (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
Woo, In-Sook (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
Han, Chi-Hwa (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
Kim, Hyo-Lim (Department of Radiology, St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
Publication Information
The Korean Journal of Medicine / v.80, no.6, 2011 , pp. 729-733 More about this Journal
Abstract
Erlotinib, an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is indicated for EGFR mutation-positive patients with poor performance status. Erlotinib is also used as a second-line agent in patients who show disease progression after failure of first-line therapy. Warfarin is administered in patients with advanced cancer for the prevention or treatment of venous thromboembolism. Both erlotinib and warfarin are metabolized in the human liver primarily by the CYP3A4 enzyme system. Thus, erlotinib may inhibit the metabolism of warfarin and clinicians should pay attention to the possible interaction between the two drugs when they are administered concurrently. We report the case of a 50-year-old man who showed changes in the prothrombin time-international normalized ratio (PT-INR) after coadministration of erlotinib and warfarin.
Keywords
Erlotinib; Warfarin; Prothrombin time; Carcinoma, Non-small cell lung;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.   DOI   ScienceOn
2 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatments, and survivorship. Mayo Clin Proc 2008;83:584-594.   DOI
3 Korean National Statistical Office. The cause of death statistics, Daejeon: Korean National statistical office, c2006. [cited 2010, March 10]. Available from: http://www.Cancer.go.kr/cms/statics/mortality/index.html.
4 Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 2005;366:1527-1537.   DOI   ScienceOn
5 Arai S, Mitsufuji H, Nishii Y, et al. Effect of gefitinib on warfarin antithrombotic activity. Int J Clin Oncol 2009;14:332-336.   DOI   ScienceOn
6 Onoda S, Mitsufuji H, Yanase N, et al. Drug interaction between gefitinib and warfarin. Jpn J Clin Oncol 2005;35:478-482.   DOI   ScienceOn
7 Micromedex Products. Erlotinib. [cited 2010. March 10]. Available from: http://www.thomsonhc.com/ hcs/ librarian.
8 Tarceva R[package insert]. Roche Pharma (Schweiz) Ltd. Schoenmattstrasse 2 4153 Reinach. Switzerland. Available from: http:// www.roche.co.kr./fmfiles/re7198001/product/insertpaper/Tarreva tab.pdf.
9 Hidalgo M, Bloedow D. Pharmacokinetics and Pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin Oncol 2003;30(3 Suppl 7):S25-S33.
10 Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther 2005;27: 1513-1534.   DOI   ScienceOn
11 Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.   DOI   ScienceOn
12 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.   DOI   ScienceOn
13 Yildirim Y, Ozyilkan O, Akcali Z, Basturk B. Drug interation between capecitabine and warfarin: a case report and review of the literature. Int J Clin Pharmacol Ther 2006;44:80-82.   DOI
14 Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol 2009;27:4874- 4680.   DOI   ScienceOn
15 Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003;41:1633-1652.   DOI   ScienceOn
16 Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction: a consecutive case series. Pharmacotherapy 1999;19:1445-1449.   DOI   ScienceOn
17 Moretti LV, Montalvo RO. Elevated internationl normalized ratio associated with concurrent use of sorafenib and warfarin. Am J Health Syst Pharm 2009;66:2123-2125.   DOI   ScienceOn
18 Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992;32:897-909.   DOI
19 Cohen MH, Williams GA, Sridhara R, et al. United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.   DOI   ScienceOn